ReviewInternational journal of nanomedicine2025
Exploring the Potential of Non-Viral Nanocarriers for Improving Blood-Brain Barrier Permeability to Enhance the Treatment of Brain Diseases.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders.Cellular and molecular neurobiology · 2026Review
- Ischemic stroke neuroprotection revisited: translational barriers and a phase-resolved, biomarker-anchored framework.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain diseases have become an important health problem worldwide, especially in the aging population, and their incidence and prevalence continue to increase. Despite remarkable progress in medical technology, the treatment of brain diseases still faces many challenges, especially limitations caused by the blood-brain barrier (BBB), which significantly hinders the delivery of therapeutic drugs to the brain. In recent years, non-viral nanocarriers developed by nanotechnology have shown great potential for crossing the BBB, and have attracted much attention due to their low immunogenicity, high biocompatibility and good targeting. In this paper, we review the basic structure of the BBB, properties of nonviral vectors, and the mechanisms of crossing BBB. Moreover, this review summarizes the main types of non-viral vectors-liposomes, polymeric nanoparticles, biomimetic materials, and inorganic nanomaterials-while addressing the main translational barriers, including low BBB permeability, poor systemic stability, nonspecific peripheral accumulation, manufacturing challenges, and limited clinical validation, and suggests future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.